SHP2 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
SHP2 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy was generated using PatSnap Life Sciences MCP Servers. Target & Disease MCP contributed the biology and disease context, while Clinical Trials MCP contributed validation evidence and clinical competition signals.
Why this report exists: it shows how AI agents can use PatSnap MCP data to produce target evaluation workflows covering biology, validation, competition, IP, and R&D recommendation. Explore PatSnap Life Sciences MCP Servers for AI agents.
Executive Summary
This SHP2 Target Evaluation Report is generated from PatSnap MCP data. PTPN11 / SHP2 is a central RAS/MAPK signaling node in NSCLC, with clinical development focused on KRAS G12C combinations, EGFR-mutant resistance, and pathway-feedback suppression.
Target
PTPN11 / SHP2
UniProt Q06124
Drug Count
128
86 development-stage assets
Trials
30
SHP2 NSCLC trials retrieved by Clinical Trials MCP
Results
2
Clinical Trials MCP result records
Target Attractiveness Snapshot
Biology
Target & Disease MCP describes SHP2 as a tyrosine phosphatase acting downstream of receptor and cytoplasmic kinases, positively regulating MAPK signaling and modulating EGFR, GAB1, ROCK2, CDC73, SOX9, and T-cell receptor signaling through PD-1 recruitment.
Disease Context
In NSCLC, SHP2 is being tested as a combination partner for KRAS G12C inhibitors and EGFR-targeted therapy.
Strategy
Differentiate through combination tolerability, pathway suppression biomarkers, and selection of KRAS- or EGFR-defined populations.
Overall Target Evaluation Score: 77/100
- Biology: MAPK pathway biology is strong and clinically relevant.
- Clinical validation: Clinical Trials MCP returned 30 NSCLC trials and 2 released result records.
- Competition: Competition is active, especially in KRAS G12C NSCLC.
- White space: White space depends on combination safety and biomarker-defined resistance settings.
Biology and Disease Rationale
SHP2 is a non-receptor protein tyrosine phosphatase encoded by PTPN11. Target & Disease MCP links it to signaling from receptor and cytoplasmic kinases to the nucleus, positive MAPK pathway regulation, EGFR and GAB1 dephosphorylation, and PD-1-mediated T-cell signaling inhibition. That dual role makes it relevant in both tumor-intrinsic signaling and immune context.
Clinical Trials MCP returned SHP2 NSCLC trials including KRAS G12C combination studies, GH21 plus osimertinib in NSCLC, BBP-398 plus osimertinib in EGFR-mutant NSCLC, and a Phase 3 comparison of JAB-21822 plus JAB-3312 versus standard of care in first-line KRAS p.G12C NSCLC.
Explore PatSnap Life Sciences MCP Servers for AI agents
Validation and Clinical Competition
| KRAS G12C Phase 3 | JAB-21822 plus JAB-3312 is recruiting in first-line advanced KRAS p.G12C NSCLC. |
| KRAS combination result | Clinical Trials MCP indexed RMC-4630 plus sotorasib Phase 2 in KRAS G12C NSCLC after standard therapy. |
| Positive front-line signal | Glecirasib plus JAB-3312 was indexed as a positive Phase 1/2 front-line treatment result in KRAS p.G12C NSCLC. |
| EGFR resistance angle | BBP-398 and GH21 combinations with osimertinib show SHP2 interest beyond KRAS G12C disease. |
IP and Competitive Strategy
SHP2 IP should compare allosteric inhibitor chemotypes, KRAS G12C and EGFR combination claims, dose schedules that manage toxicity, biomarkers for pathway rebound, and tumor-immune combination hypotheses.
Recommendation
SHP2 is a credible RAS/MAPK combination target in NSCLC. The best programs will prove tolerability and pathway suppression in a genetically defined setting rather than relying on broad MAPK-pathway rationale alone.
Bottom line: This SHP2 Target Evaluation Report is generated from PatSnap MCP data. PTPN11 / SHP2 is a central RAS/MAPK signaling node in NSCLC, with clinical development focused on KRAS G12C combinations, EGFR-mutant resistance, and pathway-feedback suppression.
Start building target evaluation agents with PatSnap Life Sciences MCP Servers
